Journal List > J Korean Neuropsychiatr Assoc > v.54(1) > 1017724

J Korean Neuropsychiatr Assoc. 2015 Feb;54(1):127-131. Korean.
Published online February 28, 2015.
Copyright © 2015 Korean Neuropsychiatric Association
A Case of Clinical Application of Covert Sensitization in a Patient with Kleptomania
Jung-Young Kim, MD,1,2 Nam-In Kang, MD, PhD,2 and Jong-Chul Yang, MD, PhD1,3
1Department of Psychiatry, Chonbuk National University Medical School, Jeonju, Korea.
2Department of Psychiatry, Jeonbuk Provincial Maeumsarang Hospital, Wanju, Korea.
3Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea.

Address for correspondence: Jong-Chul Yang, MD, PhD. Department of Psychiatry, Chonbuk National University Medical School, 20 Geonji-ro, Deokjin-gu, Jeonju 561-712, Korea. Tel +82-63-250-2580, Fax +82-63-275-3157, Email:
Received December 19, 2014; Revised December 27, 2014; Accepted December 30, 2014.


Kleptomania is a well-known impulse-control disorder. Although it is a rare disease, it exerts a greater influence on the social and economic. There are a variety of treatments for kleptomania, however case reports of its specific treatment techniques are extremely rare. In this case, covert sensitization was applied to a 44-year-old hospitalized patient with kleptomania, which can facilitate a specific treatment method through case presentation.

Keywords: Kleptomania; Covert sensitization; Cognitive behavior therapy


The authors have no financial conflicts of interest.

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Goldman MJ. Kleptomania: making sense of the nonsensical. Am J Psychiatry 1991;148:986–996.
3. Grant JE, Kim SW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry 2002;43:378–384.
4. Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007;68:422–427.
5. Grant JE, Kim SW, Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry 2009;65:600–606.
6. Grant JE. Understanding and treating kleptomania: new models and new treatments. Isr J Psychiatry Relat Sci 2006;43:81–87.
7. Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004;16:27–34.
8. Grant JE, Odlaug BL. [Kleptomania: clinical characteristics and treatment]. Rev Bras Psiquiatr 2008;30 Supple 1:S11–S15.
9. Grant JE, Odlaug BL, Davis AA, Kim SW. Legal consequences of kleptomania. Psychiatr Q 2009;80:251–259.
10. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. Compr Psychiatry 2002;43:7–12.
11. Fishbain DA. Kleptomania as risk-taking behavior in response to depression. Am J Psychother 1987;41:598–603.
12. McElroy SL, Pope HG Jr, Hudson JI, Keck PE Jr, White KL. Kleptomania: a report of 20 cases. Am J Psychiatry 1991;148:652–657.